Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TOP2A | P11388 | 1/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9720744 | 1.00 | PTGS1 (0.56) | PTGS1LMNATOP2ATOP2BPIK3CD | |
| SCHEMBL9720830 | 1.00 | PTGS1 (0.56) | PTGS1LMNATOP2ATOP2BPIK3CD | |
| SCHEMBL14021775 | 0.89 | PTGS1 (0.50) | PTGS1LMNATOP2ATOP2BPIK3CD | |
| SCHEMBL14006928 | 0.88 | TOP2A (0.77) | PTGS1LMNATOP2ATOP2BPIK3CD | |
| SCHEMBL11929245 | 0.88 | TOP2A (0.77) | PTGS1LMNATOP2ATOP2BPIK3CD | |
| SCHEMBL17471506 | 0.88 | TOP2A (0.77) | PTGS1LMNATOP2ATOP2BPIK3CD | |
| SCHEMBL14006924 | 0.88 | TOP2A (0.77) | PTGS1LMNATOP2ATOP2BPIK3CD | |
| SCHEMBL9720750 | 0.77 | PIK3CD (0.37) | PTGS1LMNATOP2ATOP2BPIK3CD | |
| SCHEMBL10622995 | 0.77 | PTGS1 (0.45) | PTGS1LMNATOP2ATOP2BPIK3CD | |
| SCHEMBL11092444 | 0.75 | PTGS1 (0.47) | PTGS1LMNATOP2ATOP2BPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008134630-A1 | DEXRAZOXANE COMPOUNDS FOR CARDIOPROTECTION | APT PHARMACEUTICALS (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275036-A1 | Prevention and treatment of cardiac conditions | APT PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275036-A1 | Prevention and treatment of cardiac conditions | APT PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| WO-2007053415-A2 | AGENTS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-1992000740-A2 | BIS-DIOXOPIPERAZINES AND THEIR USE AS PROTECTION AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275036-A1 | Prevention and treatment of cardiac conditions | TNNT2, TNNI3, TNNC1 | PTGS1 342/4885LMNA 638/4885TOP2A 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.